BRESCIA MORRA, VINCENZO
 Distribuzione geografica
Continente #
AS - Asia 13.289
NA - Nord America 12.390
EU - Europa 8.930
SA - Sud America 1.651
Continente sconosciuto - Info sul continente non disponibili 783
AF - Africa 317
OC - Oceania 21
Totale 37.381
Nazione #
US - Stati Uniti d'America 11.758
SG - Singapore 5.621
RU - Federazione Russa 3.799
VN - Vietnam 2.502
CN - Cina 2.457
IT - Italia 2.044
BR - Brasile 1.291
HK - Hong Kong 1.145
DE - Germania 663
FR - Francia 468
NL - Olanda 431
CA - Canada 361
FI - Finlandia 333
GB - Regno Unito 303
IN - India 277
JP - Giappone 247
BD - Bangladesh 240
UA - Ucraina 199
IE - Irlanda 183
AR - Argentina 158
MX - Messico 120
KR - Corea 115
SE - Svezia 108
ZA - Sudafrica 100
IQ - Iraq 87
CI - Costa d'Avorio 85
PH - Filippine 85
PL - Polonia 79
ES - Italia 76
ID - Indonesia 64
TH - Thailandia 63
IR - Iran 61
AT - Austria 57
EC - Ecuador 51
TR - Turchia 47
CO - Colombia 40
PK - Pakistan 39
TW - Taiwan 38
LT - Lituania 33
VE - Venezuela 33
BE - Belgio 29
SA - Arabia Saudita 26
JM - Giamaica 25
MA - Marocco 21
CL - Cile 19
MY - Malesia 19
CR - Costa Rica 18
EG - Egitto 18
PY - Paraguay 18
NI - Nicaragua 17
PE - Perù 17
UZ - Uzbekistan 17
KE - Kenya 16
NP - Nepal 16
AE - Emirati Arabi Uniti 15
DO - Repubblica Dominicana 15
JO - Giordania 15
TN - Tunisia 15
CZ - Repubblica Ceca 14
HN - Honduras 14
AU - Australia 11
BO - Bolivia 11
DK - Danimarca 11
DZ - Algeria 11
IL - Israele 10
TT - Trinidad e Tobago 10
UY - Uruguay 10
BB - Barbados 9
GR - Grecia 9
LB - Libano 9
OM - Oman 9
RS - Serbia 9
AZ - Azerbaigian 8
CH - Svizzera 8
AL - Albania 7
AM - Armenia 7
GT - Guatemala 7
HR - Croazia 7
KZ - Kazakistan 7
MK - Macedonia 7
PA - Panama 7
EE - Estonia 6
GE - Georgia 6
LV - Lettonia 6
NG - Nigeria 6
NZ - Nuova Zelanda 6
PT - Portogallo 6
SK - Slovacchia (Repubblica Slovacca) 6
SV - El Salvador 6
BG - Bulgaria 5
ET - Etiopia 5
MN - Mongolia 5
SY - Repubblica araba siriana 5
XK - ???statistics.table.value.countryCode.XK??? 5
CU - Cuba 4
KG - Kirghizistan 4
PR - Porto Rico 4
QA - Qatar 4
RO - Romania 4
SN - Senegal 4
Totale 36.506
Città #
Singapore 2.644
San Jose 2.348
Ashburn 1.114
Hong Kong 1.088
Moscow 927
Chandler 754
Ho Chi Minh City 711
Beijing 670
Hanoi 557
Santa Clara 543
Hefei 514
Naples 468
Council Bluffs 368
Los Angeles 359
Amsterdam 351
Lauterbourg 273
Millbury 249
Tokyo 230
The Dalles 223
New York 201
Dallas 193
Munich 189
Princeton 180
Napoli 174
Nanjing 148
Buffalo 137
Milan 137
Boston 135
Des Moines 127
São Paulo 126
Phoenix 119
Redondo Beach 108
Haiphong 107
Rome 102
Seattle 101
Frankfurt am Main 89
Wilmington 89
Da Nang 87
Helsinki 86
Norwalk 86
Seoul 84
Orem 80
Chicago 78
Ottawa 78
Lawrence 74
Jacksonville 72
Toronto 70
Denver 68
Montreal 68
Warsaw 67
Houston 65
Turku 60
Mexico City 57
Dong Ket 56
London 56
Chennai 53
Stockholm 52
Johannesburg 50
Tianjin 50
Brooklyn 49
Nanchang 47
Dublin 46
Rio de Janeiro 45
Nuremberg 43
Atlanta 42
Falkenstein 41
Baghdad 34
Poplar 34
Biên Hòa 33
Can Tho 33
Krefeld 33
Hebei 29
Hải Dương 29
Augusta 28
San Francisco 28
Charlotte 27
Lappeenranta 27
Vienna 26
Brasília 25
Mumbai 25
Newark 25
Pune 25
Belo Horizonte 24
Jiaxing 24
Washington 24
Guangzhou 23
Quito 23
Curitiba 22
Manchester 22
Thái Nguyên 22
Ankara 21
Bangkok 21
Bari 21
Paris 21
Phủ Lý 21
Cava De' Tirreni 20
Shenyang 20
Boardman 19
Bắc Giang 19
Ninh Bình 19
Totale 19.510
Nome #
AQP4-MOG Double-Positive Neuromyelitis Optica Spectrum Disorder: Case Report with Central and Peripheral Nervous System Involvement and Review of Literature 284
Quality of Life and Cognitive function in pediatric and young adults multiple sclerosis: a cross-sectional study 240
Deciphering the role of protein kinase A in the control of FoxP3 expression in regulatory T cells in health and autoimmunity 228
Uric acid: a potential biomarker of multiple sclerosis and of its disability 213
ChatGPT vs. neurologists: a cross-sectional study investigating preference, satisfaction ratings and perceived empathy in responses among people living with multiple sclerosis 206
The ocrelizumab wearing-off phenomenon is associated with reduced immunomodulatory response and increased neuroaxonal damage in multiple sclerosis 198
Corpus callosum involvement: a useful clue for differentiating Fabry Disease from Multiple Sclerosis 195
MRI features suggestive of gadolinium retention do not correlate with Expanded Disability Status Scale worsening in Multiple Sclerosis 190
A clinical comparison of trigeminal neuralgic pain in patients with and without underlying multiple sclerosis 189
Glatiramer Acetate modulates ion channels expression and calcium homeostasis in B cell of patients with relapsing-remitting multiple sclerosis 188
Immunometabolic profiling of T cells from patients with relapsing-remitting multiple sclerosis reveals an impairment in glycolysis and mitochondrial respiration 181
2D linear measures of ventricular enlargement may be relevant markers of brain atrophy and long-term disability progression in multiple sclerosis 178
Incidence and Prevalence of Dementia: A 2015-2020 Population-Based Study in the Campania Region of Italy 177
A randomized controlled pilot trial of lithium in spinocerebellar ataxia type 2. 176
Vascular alterations in multiple sclerosis and amyotrophic lateral sclerosis : preliminary analysis of susceptibility factors 175
Atorvastatin combined to interferon to verify the efficacy (ACTIVE) in relapsing-remitting active multiple sclerosis patients: a longitudinal controlled trial of combination therapy. 173
Affective disorders and Health-Related Quality of Life (HRQoL) in adolescents and young adults with Multiple Sclerosis (MS): the moderating role of resilience 172
The use of medical-grade cannabis in patients non-responders to Nabiximols 171
Cognitive impairment at diagnosis predicts 10-year multiple sclerosis progression 169
Coenzyme Q10 supplementation reduces peripheral oxidative stress and inflammation in interferon-β1a-treated multiple sclerosis 169
Prognostic Markers of Ocrelizumab Effectiveness in Multiple Sclerosis: A Real World Observational Multicenter Study 168
The effect of air pollution on COVID-19 severity in a sample of patients with multiple sclerosis 168
Validation of an iPad version of the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) 167
Determinants of Deep Gray Matter Atrophy in Multiple Sclerosis: A Multimodal MRI Study 167
Pediatric-onset Multiple Sclerosis treatment: a multicentre observational study comparing natalizumab with fingolimod 163
SPG5 and multiple sclerosis: clinical and genetic overlap? 163
Validation of the Italian version of the Multiple Sclerosis Intimacy and Sexuality Questionnaire-19 163
JCV antibodies index on natalizumab treatment: fluctuations and seroconversion. 160
Quality of Life Changes in Early-Onset Multiple Sclerosis: A 4-Year Follow-Up Study 159
Being highly sensitive person negatively impacts on cognitive and psychosocial fatigue in multiple sclerosis patients: A cross-sectional, monocenter study 159
Peripapillary Vessel Density as Early Biomarker in Multiple Sclerosis 159
Multiple sclerosis and headache co-morbidity. A case-control study 158
Epileptic seizures in multiple sclerosis: clinical and EEG correlations. 158
In vivo dentate nucleus MRI relaxometry correlates with previous administration of Gadolinium-based contrast agents 157
Striatonigral involvement in Fabry Disease: A quantitative and volumetric Magnetic Resonance Imaging study 157
Quality of life and cognitive functions in early onset multiple sclerosis 156
Normative values of the Rao’s Brief Repeatable Battery in an Italian young adolescent population: the influence of age, gender, and education 155
Changes in lymphocytes, neutrophils and immunoglobulins in year-1 cladribine treatment in multiple sclerosis 154
Imaging of brain perfusion in multiple sclerosis and neurodegenerative disorders: association with endothelial factors. An interim analysis. In MULTIPLE SCLEROSIS JOURNAL (Vol. 20, pp. 297-297). 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND: SAGE PUBLICATIONS LTD. 154
Fertility, pregnancy and childbirth in women with multiple sclerosis: a population-based study from 2018 to 2020 153
Levetiracetam for cerebellar tremor in multiple sclerosis: an open-label pilot tolerability and efficacy study. 153
Post-mortem diagnosis of invasive pulmonary aspergillosis after alemtuzumab treatment for multiple sclerosis 153
Prevalence and Incidence of Paramagnetic Rim Lesions in Multiple Sclerosis: A Systematic Review and Meta-Analysis 152
Grey matter loss in relapsing-remitting multiple sclerosis: a voxel-based morphometry study. 152
L'attenzione alle donne nei servizi psicologici offerti dal Centro Regionale Sclerosi Multipla ''Federico II'' di Napoli: l'esperienza del progetto SIM 152
Signs and symptoms of COVID-19 in patients with multiple sclerosis 151
Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study 151
How many injections did you miss last month? A simple question to predict interferon β-1a adherence in multiple sclerosis 151
Absence of infratentorial lesions in Fabry disease contributes to differential diagnosis with multiple sclerosis 151
Neurofilament light chain and Alzheimer pathology biomarkers in elderly people with multiple sclerosis 150
Tango classes in people with Multiple Sclerosis (PwMS): Impact on motor and non-motor functions 150
The combined use of conventional MRI and MR spectroscopic imaging increases the diagnostic accuracy in amyotrophic lateral sclerosis. 150
Dimethyl Fumarate Mediates Nrf2-dependent Mitochondrial Biogenesis in Mice and Humans 150
Signals of pseudo-starvation unveil the amino acid transporter SLC7A11 as key determinant in the control of Treg cell proliferative potential 150
Effect of siponimod on lymphocyte subsets in active secondary progressive multiple sclerosis and clinical implications 149
Correction to: Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study (Journal of Neurology, (2022), 269, 6, (3301-3307), 10.1007/s00415-022-11009-x) 149
Clinical correlates of R1 relaxometry and magnetic susceptibility changes in multiple sclerosis: a multi-parameter quantitative MRI study of brain iron and myelin 149
Persistence, adherence, healthcare resource utilisation and costs for interferon Beta in multiple sclerosis: a population-based study in the Campania region (southern Italy) 149
Cognitive trajectories in multiple sclerosis: a long-term follow-up study 149
Concomitant diagnosis of multiple sclerosis and human immunodeficiency virus (HIV) infection: case report and the review of literature 148
Persistence with Botulinum Toxin Treatment for Spasticity Symptoms in Multiple Sclerosis 148
A randomized controlled clinical trial of growth hormone in amyotrophic lateral sclerosis: clinical, neuroimaging, and hormonal results. 148
The IFN-β 1b effect on Cu Zn superoxide dismutase (SOD1) in peripheral mononuclear blood cells of relapsing-remitting multiple sclerosis patients and in neuroblastoma SK-N-BE cells 148
CD4/CD8 ratio during natalizumab treatment in multiple sclerosis patients 148
Reduced intracranial volume in Fabry Disease: Evidence of abnormal neurodevelopment? 148
MicroRNA-142-3p shuttling in extracellular vesicles marks regulatory T cell dysfunction in multiple sclerosis 147
Clinical application of age-derived cut-offs for plasma neurofilament light chain in multiple sclerosis 147
Immunometabolic profiling of patients with multiple sclerosis identifies new biomarkers to predict disease activity during treatment with interferon beta-1a 147
Mental Health in Multiple Sclerosis During the COVID-19 Outbreak: A Delicate Balance between Fear of Contagion and Resilience 147
Pragmatic abilities in multiple sclerosis: The contribution of the temporo-parietal junction 146
The central vein sign helps in differentiating multiple sclerosis from its mimickers: lessons from Fabry disease 145
Lamivudine and fingolimod co-administration in two patients with multiple sclerosis and occult hepatitis B virus infection 145
Quality of life and cognitive function in pediatric and young multiple sclerosis patients: a cross-sectional study 145
Determinants of early working impairments in multiple sclerosis 144
Cerebellar lobule atrophy and disability in progressive MS 144
Uric acid in relapsing–remitting multiple sclerosis: a 2-year longitudinal study 143
Default mode network modifications in Fabry disease: A resting-state fMRI study with structural correlations 143
Retinal vascular density in multiple sclerosis: a one year follow up 141
Risk of invasive fungal infections among patients treated with disease modifying treatments for multiple sclerosis: a comprehensive review 141
ProspeCtive study to evaluate efficacy, safety and tOlerability of dietary supplemeNT of Curcumin (BCM95) in subjects with Active relapsing MultIple Sclerosis treated with subcutaNeous Interferon beta 1a 44 mcg TIW (CONTAIN): A randomized, controlled trial 141
Impact of an anti-infective screening and monitoring protocol together with infectious disease consultation in preventing infective adverse events in patients treated with anti-CD20/CD52 agents for multiple sclerosis 140
Sexual dysfunction in multiple sclerosis: The impact of different MSISQ-19 cut-offs on prevalence and associated risk factors 140
Lack of correlation between extracranial venous abnormalities and multiple sclerosis: a quantitative MRI study 140
Brain Susceptibility Changes in a Patient with Natalizumab-Related Progressive Multifocal Leukoencephalopathy: A Longitudinal Quantitative Susceptibility Mapping and Relaxometry Study 140
A clinical comparison of trigeminal neuralgic pain in patients with and without underlying multiple sclerosis 139
Multiple Sclerosis in the Campania Region (South Italy): Algorithm Validation and 2015-2017 Prevalence 139
Exploring the relation between reserve and fatigue in multiple sclerosis 138
Optical coherence tomography angiography in optic nerve sheath meningioma 138
Prevalence of GLA gene mutations and polymorphisms in patients with multiple sclerosis: A cross-sectional study 138
Physical Exercise Moderates the Effects of Disability on Depression in People with Multiple Sclerosis during the COVID-19 Outbreak 138
Ocrelizumab depletes T-lymphocytes more than rituximab in multiple sclerosis 138
COVID-19 pandemic and mental distress in Multiple Sclerosis: implications for clinical management 137
A multiple n-glucosylated peptide epitope efficiently detecting antibodies in multiple sclerosis 137
Long-term clinical experience with weekly interferon beta-1a in relapsing multiple sclerosis 136
Pregnancy Epigenetic Signature in T Helper 17 and T Regulatory Cells in Multiple Sclerosis 136
Brain tissue volumes and relaxation rates in multiple sclerosis: implications for cognitive impairment 136
Healthcare resource utilization and costs for multiple sclerosis management in the Campania region of Italy: Comparison between centre-based and local service healthcare delivery 136
Treatment of multiple sclerosis with rituximab: A multicentric Italian–Swiss experience 136
A randomized clinical trial of lithium in multiple system atrophy. 135
Predictors of Nabiximols (Sativex®) discontinuation over long-term follow-up: a real-life study 135
Totale 15.737
Categoria #
all - tutte 125.763
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 125.763


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.331 0 0 12 16 28 78 22 58 177 116 274 550
2022/20232.204 264 175 54 110 235 255 164 172 323 316 98 38
2023/20241.603 51 238 232 103 78 182 71 162 23 38 280 145
2024/20259.027 437 457 49 128 296 521 909 564 691 1.021 3.106 848
2025/202618.665 1.889 1.405 1.807 1.870 3.241 628 2.086 1.189 2.284 1.327 472 467
2026/20271.862 425 812 625 0 0 0 0 0 0 0 0 0
Totale 37.381